SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
AEOLUS PHARMACEUTICALS INC
(NQPK:AOLS Last Sale: .24 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQPK: (AOLS : $.24)
$15 million Market Cap at September 12, 2013
Drugs SubIndustry up .00% / Health Industry up .00% Today
Mission Viejo, CA Research Report Earnings Snapshot - Last 05/15/17
Fact Sheet
Financial Statements
Peer Comparison
Annual Reports


developing a new platform technology from Duke University and National Jewish Health. Three compounds are currently in development. Aeolus’ lead compound, AEOL 10150, not only protects healthy tissue from the damaging effects of radiation, but also helps increase tumor control when used in combination with radiation and chemotherapy. Aeolus’ strategy is to leverage the substantial investment by the US Government in developing its lead compound as a medical countermeasure to pulmonary effects of Acute Radiation Syndromes (Lung-ARS) to develop it in oncology, where it would be used in combination therapy.
Historical Charts    Technical Analysis
No Historical Data available for AOLS

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common AOLS $.24 $ 0 $.23 $.25 58,232 $.22 $.475 62,731
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $15,055

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex